Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
r&dtechnical
Research and development (R&D) is the work a company does to discover new products, improve existing ones, or develop better ways of making things — like a kitchen testing recipes to create a hit dish. For investors it matters because R&D is where future sales and competitive advantages are born, but it also uses cash and carries risk, so R&D spending and outcomes signal a company’s growth potential and uncertainty.
digital healthmedical
Digital health involves the use of technology, such as apps, wearable devices, and online platforms, to monitor, manage, and improve people's health and healthcare. For investors, it represents a growing industry that combines healthcare with digital innovation, offering new ways to deliver medical services and track wellness, which can lead to advancements in patient care and potential business opportunities.
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
WILMINGTON, Del.--(BUSINESS WIRE)--
AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.
Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally.
The investment underpins AstraZeneca’s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company’s largest market.
Suarez said: “We are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value.”
Suarez will have full responsibility for AstraZeneca’s US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.
Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca’s strongest performing European markets. He expanded Spain’s role in global clinical development and positioned Barcelona as a strategic hub for innovation.
During his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.
Suarez will be based at AstraZeneca’s US headquarters in Wilmington, Delaware. His appointment is effective immediately.
Biographical information
Rick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.
Notes
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
